Study Details
Studying Lebrikizumab Treatment for People with Moderate-to-Severe Atopic Dermatitis
(IRB#: IRB_00187094)
Atopic dermatitis (eczema) is a chronic skin condition that may cause itchy, red, dry patches of sensitive skin. Lebrikizumab is a drug used to treat people with this condition. This study wants to see how well the drug works to help adults and children with the condition. Being in the study requires attending 6 visits to the study clinic for about 2 years. Medical information will be collected during the study to track the health of participants.
- All genders
- Over 7 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 7 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages 12 years and older
- Diagnosis of moderate to severe Atopic Dermatitis at least 6 months before study participation
- Able to have the Lebrikizumab treatment as part of regular care
- Able to attend in-person study visits at the clinic
Exclusion Criteria
- Previous use of Lebrikizumab
- Previous participation in the study
- Current participation in another clinical study
- Hypersensitivity to Lebrikizumab
- Lilly employees
Will I be paid for my time?
Yes
IRB#: IRB_00187094
PI: Jamie Schlarbaum
Department: DERMATOLOGY
Approval Date: 2025-08-25 19:50:00
Specialties: Dermatology
I am Interested